Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Fractional Shares

2,020.88
+16.530.82%
Number of Gainers:615
Number of Losers:390
Number of Flat:16
PE:- -
High:2,028.19
Open:2,004.58
Low:2,004.58
Close:2,004.35
Volume:6.06B
Turnover:742.41B
Market Cap:96.59T
Float Cap:90.42T

Loading ...

OverviewNews

Why Fair Isaac Stock is Surging After Its Worst Quarter on Record

Dow Jones
·
Oct 01

EIA Reports 64-Bcf Injection in Natural Gas Storage

Dow Jones
·
Oct 01

Foghorn Stock Craters as Lilly Scraps Cancer Deal, Forcing Nearly Half of Staff Layoffs

Dow Jones
·
Oct 01

Experts Including Dalio Advise on How to Protect Wealth: 'We Are in a Bubble'

Deep News
·
Oct 01

Update: Market Chatter: Vale Eyes China Bond Debut to Diversify Funding Sources

MT Newswires Live
·
Oct 01

Top Midday Stories: Micron Shares Fall Despite Strong Earnings, Guidance; Broadcom to Lend Anthropic $42 Billion for Infrastructure Spending

MT Newswires Live
·
Oct 01

Synchrony Financial Price Target Cut to $80.00/Share from $86.00 by Evercore ISI Group

Dow Jones
·
Oct 01

Workday announces launch of operations in United Arab Emirates

TIPRANKS
·
Oct 01

Regeneron says COURAGE trial confirms trevogrumab prevents muscle loss

TIPRANKS
·
Oct 01

Datadog put volume heavy and directionally bearish

TIPRANKS
·
Oct 01

Regeneron Pharmaceuticals, - 9-Month Median Duration of Response Observed at 800 Mg Ubamatamab Dose

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Ubamatamab Shows 73% Objective Response Rate and 11-Month Median Pfs in Lgsoc Patients

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Serious Teaes Grade 3+ in 21% of Lgsoc Patients; Traes in 74%; Neutropenia, Anemia, Elevated Liver Enzymes

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - to Advance Ubamatamab into Confirmatory Phase 3 Trial for Lgsoc

THOMSON REUTERS
·
Oct 01

Ubamatamab (Muc16xcd3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (Lgsoc)

THOMSON REUTERS
·
Oct 01

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

GlobeNewswire
·
Oct 01

AJ Bell Confirms Total Voting Rights and Share Capital Structure

TIPRANKS
·
Oct 01

Anglo American Executives Reinvest Interim Dividend in Company Shares

TIPRANKS
·
Oct 01

NAND Supply Tightness Could Persist Through 2028; Citi Bullish on AI-Driven Memory Chip Price Hikes, Reiterates Buy Rating on SanDisk (SNDK.US)

Stock News
·
Oct 01

Walmart Stock Shines as Its App Helps Customers See the Light and the Peanut Butter

TIPRANKS
·
Oct 01
More